Investigation of the Contents and Prognostic Values of Glucose Metabolism Molecules in Patients With Lung Adenocarcinoma

• Sponsor: Shanghai Zhongshan Hospital (Other)
• Overall Status: Unknown status
• CT.gov ID: NCT03641105
• Collaborator: (none)
• Enrollment: 100
• Anticipated Duration (Months): 61.9

Study Details

Study Description

Brief Summary

Detect the contents of glucose metabolism molecules in the tumor and adjacent normal samples of about 100 patients with lung adenocarcinoma using mass spectroscopy. Analyze the correlation between the contents and the clinicopathological characteristics and survival.

Condition or Disease	Intervention/Treatment	Phase
Lung Cancer; Glycolysis; Diagnosis; Survival	Diagnostic Test: Diagnostic test

Study Design

• Study Type: Observational [Patient Registry]
• Anticipated Enrollment: 100 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Investigation of the Contents and Prognostic Values of Glucose Metabolism Molecules in Patients With Lung Adenocarcinoma
• Actual Study Start Date: Jan 1, 2014
• Anticipated Primary Completion Date: Mar 1, 2019
• Anticipated Study Completion Date: Mar 1, 2019

Arms and Interventions

Arm	Intervention/Treatment
lung adenocarcinoma patients with lung adenocarcinoma	Diagnostic Test: Diagnostic test; detect the contents of glucose metabolism molecules using mass spectrum

Outcome Measures

Primary Outcome Measures

1. disease-free survival [1 month]

   disease-free survival

Secondary Outcome Measures

1. overall survival [1 month]

   overall survival

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Primary lung adenocarcinoma

Exclusion Criteria:

• Other tumor histories, received radiotherapy or chemotherapy before surgery, tumor or adjacent normal tissues can't be obtained, patient rejected.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• Shanghai Zhongshan Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Shanghai Zhongshan Hospital
• ClinicalTrials.gov Identifier: NCT03641105
• Other Study ID Numbers: ZST-GLUMETA
• First Posted: Aug 21, 2018
• Last Update Posted: Aug 21, 2018
• Last Verified: Aug 1, 2018

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Adenocarcinoma; Adenocarcinoma of Lung

Study Results

No Results Posted as of Aug 21, 2018